Jagsonpal Pharma Acquires Group Pharma Wellness Portfolio

• Jagsonpal Pharmaceuticals Limited acquired the wellness portfolio division of Group Pharmaceuticals Limited.
• The transaction was conducted on a slump sale basis, transferring the business as a going concern.
• ThinkLaw provided end-to-end legal counsel to Jagsonpal, including due diligence and drafting the business transfer agreement.
• The acquisition grants Jagsonpal an established wellness product portfolio and an existing market presence.
• Jagsonpal plans to integrate the new portfolio with its current commercial platform and capabilities.

This transaction provides a practical precedent for lawyers advising on slump sale acquisitions, particularly within the Indian pharmaceutical and wellness sectors, highlighting the critical role of legal due diligence and business transfer agreement drafting.

Jagsonpal Pharmaceuticals Limited (JPL) has successfully completed the acquisition of the entire wellness portfolio division from Group Pharmaceuticals Limited. This strategic transaction was executed on a slump sale basis, a common method in India for transferring an undertaking as a going concern without assigning individual values to assets and liabilities.

This acquisition marks a significant move for Jagsonpal, integrating an established range of wellness products into its existing operations. The deal underscores a growing trend in the pharmaceutical sector towards expanding into the lucrative wellness market through targeted mergers and acquisitions.

ThinkLaw provided comprehensive legal advisory services to Jagsonpal Pharmaceuticals Limited throughout the acquisition process. Their involvement was critical, encompassing a thorough legal due diligence on the target business to ensure compliance and mitigate risks associated with the transfer of assets and operations.

Beyond due diligence, ThinkLaw was instrumental in the drafting and negotiation of the business transfer agreement (BTA) and all other necessary transaction documents. The firm offered end-to-end legal counsel to JPL, guiding them through every stage of the deal, including assistance with the crucial closing actions. This transaction provides a practical precedent for lawyers advising on slump sale acquisitions, particularly within the Indian pharmaceutical and wellness sectors, highlighting the critical role of legal due diligence and business transfer agreement drafting.

The acquisition is set to significantly bolster Jagsonpal's market position by providing an established portfolio of wellness products and an immediate, existing market presence. This strategic move allows JPL to bypass the lengthy process of developing new products and establishing distribution channels from scratch, leveraging Group Pharma's existing infrastructure and brand recognition within the wellness segment.

Jagsonpal Pharmaceuticals Limited intends to seamlessly combine this newly acquired portfolio with its current commercial platform and capabilities. The successful execution of this deal, facilitated by ThinkLaw's expert legal guidance, demonstrates the firm's proficiency in handling complex pharmaceutical wellness M&A transactions. The ThinkLaw team, led by Partner Ankita Kashyap with strategic inputs from Founder and Managing Partner Tushar Ajinkya, and supported by Associate Partner Saahil Bijliwala, Senior Associates Parth Mehta and Kaushik Krishnan, and Associates Darshit Vora and Simran Lakra, played a pivotal role in ensuring the smooth conclusion of the Jagsonpal Group Pharma deal.

This transaction provides a practical precedent for lawyers advising on slump sale acquisitions, particularly within the Indian pharmaceutical and wellness sectors, highlighting the critical role of legal due diligence and business transfer agreement drafting. It also showcases ThinkLaw's expertise in handling such complex M&A deals.

Source: Original reporting via Bar & Bench